Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday September 29, 2009

DrStockPick.com Stock Report!

**************************************************************

CONMED Corporation (NASDAQ: CNMD), a medical technology company specializing in medical devices for surgical and patient monitoring markets, announced today that the Company will participate in the Fourth Annual JMP Securities Healthcare Focus Conference, on Tuesday, October 6, 2009 at 10:00 AM Eastern time. The event will be held in New York at the New York Palace Hotel.

Patient Access Solutions, Inc. (Pink Sheets:PASO), a leading provider of healthcare/financial processing solutions for the healthcare, homecare, nursing LTNC and dental

...

DrStockPick.com Stock Report!

Thursday July 30, 2009

**************************************************************

Waste Management, Inc. (NYSE:WMI) today announced financial results for its second quarter ended June 30, 2009. Net income(a) for the quarter was $247 million, or $0.50 per diluted share, compared with $318 million, or $0.64 per diluted share, for the second quarter of 2008. Revenues for the second quarter of 2009 were $2.95 billion compared with $3.49 billion for the same 2008 period. Only $186 million of the revenue decline, or 5.3% of revenue, was related to the impact of lower volumes in the solid waste collection and disposal business. The majority of the decline was due to commodity impacts related to recycling materials, fuel and energy sales,

...

Orchid Cellmark Inc. (ORCH) is a leading provider of DNA testing services for forensic, human identity and agricultural applications in the U.S. and the U.K.Through its facility in the U.K., Orchid conducted genotyping services under the U.K. government's project to help British farmers breed sheep with reduced susceptibility to the animal disease scrapie. The company expanded its reach in the U.S. with the acquisition of ReliaGene in October 2007.The company is now leveraging its expertise in DNA testing to enter into new markets like pork traceability, immigration testing and security applications. The company has won a major part of the mega tender in the U.K., which will result in annual revenues of $10 million for the next 3 years.We believe it is the right time to accumulate Orchid stock as we anticipate significant appreciation in the stock price in the near future. ...

Orchid Cellmark Inc. (ORCH) is a leading provider of DNA testing services for forensic, human identity and agricultural applications in the U.S. and the U.K. The company is also the world's largest provider of "scrapie susceptibility genotyping."The company expanded its reach in the U.S. with the acquisition of ReliaGene in October 2007. The company is now leveraging its expertise in DNA testing to enter into new markets like pork traceability, immigration testing and security applications. Orchid Cellmark has won a major part of the mega-tender in the U.K., which will result in annual revenues of $10 million for the next 3 years. As such, we maintain our Buy rating on the stock with a revised target price of $2.50.Maharathi Basu contributed to this report.Read the full analyst report on ORCH "ORCH" Free Stock Analysis: Buy? ...